UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment.

Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, Galanello R.SourceDipartimento di Sanità Pubblica, Medicina Clinica e Molecolare, Sezione di Scienze Biomediche e Biotecnologie, Università di Cagliari, Ospedale Regionale per le Microcitemie ASL8, Cagliari, Italy. Electronic address: fabdanjou@tiscali.it.
Blood cells, molecules & diseases.Blood Cells Mol Dis.2013 Oct;51(3):142-5. doi: 10.1016/j.bcmd.2013.06.001. Epub 2013 Jun 28.
Iron chelators and nuclear magnetic resonance imaging (MRI) techniques for assessing iron loading in liver and heart have greatly improved survival of thalassemic patients suffering iron overload-associated cardiomyopathy. However, the correlation between liver iron concentration and myocardial side
PMID 23816436

Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.

Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A.SourceInserm U1088, Faculté de Médecine, Université de Picardie Jules Verne, Amiens, France; Laboratoire de Biochimie, CHU Amiens, France.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Oct 1;133(7):1732-42. doi: 10.1002/ijc.28159. Epub 2013 Apr 8.
The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of sorafenib on HCC cells. We report that the depletion of the intracellular iron stores achieved by using the iron chelator defer
PMID 23505071

Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.

Lu W, Zhao M, Rajbhandary S, Xie F, Chai X, Mu J, Meng J, Liu Y, Jiang Y, Xu X, Meng A.SourceThe First Central Clinical College of Tianjin Medical University, Tianjin First Central Hospital, Tianjin, China.
European journal of haematology.Eur J Haematol.2013 Sep;91(3):249-61. doi: 10.1111/ejh.12159. Epub 2013 Jul 15.
OBJECTIVES: Transfusional iron overload is of major concern in hematological disease. Iron-overload-related dyserythropoiesis and reactive oxygen species (ROS)-related damage to hematopoietic stem cell (HSC) function are major setbacks in treatment for such disorders. We therefore aim to investigate
PMID 23772810

症例報告 Secondary Hemochromatosis Accompanied by Diabetes Mellitus and Hypogonadism

Nagai Takashi,Imamura Makoto,Negishi Teruo [他],Mori Masatomo
The KITAKANTO medical journal 55(2), 145-149, 2005-05-01
… After 30 months serum ferritin had decreased gradually to the normal range after daily 1,000mg injection of deferoxamine mesilate. …
NAID 110001801382

山辺習,菅野秀貴
日本耳鼻咽喉科學會會報 101(8), 979-987, 1998-08-20
… We investigated the possibility of ototoxicity by deferoxamine mesilate (DFO). …
NAID 10005598485

渡部浩伸,菅野秀貴
日本耳鼻咽喉科學會會報 101(8), 967-978, 1998-08-20
… On the other hand, deferoxiamine mesilate (DFO), an iron chelating agent, has been used for iron overloaded patients. …
NAID 10005598420